Randomized study to evaluate the efficacy and safety of nafamostat mesilate use during continuous renal replacement therapy in acute kidney injury patients at a high risk of bleeding.

Patients were randomly assigned to the nafamostat mesilate (NM) group or the no anticoagulant (NA) group. In patients assigned to the NM group, NM (20mg/h) was used for maintenance anticoagulation. Whereas, in patients assigned to the NA group, normal saline (2mL/h) was infused for continuous renal replacement therapy.

Inclusion Criteria:

• Patients who were admitted to the intensive care unit and required CRRT

  1. active bleeding such as gastrointestinal bleeding and intracranial hemorrhage,
  2. activated partial thromboplastin time > 60 s,
  3. prothrombin time-international normalized ratio > 2.0,
  4. thrombocytopenia (<100,000/µL), and
  5. surgery within 48 h before CRRT.

Exclusion Criteria:

• Pregnant or possibly pregnant women
• Patients who were allergic to nafamostat mesilate
• Patients who were hypercoagulable